JP2011524340A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011524340A5 JP2011524340A5 JP2011509829A JP2011509829A JP2011524340A5 JP 2011524340 A5 JP2011524340 A5 JP 2011524340A5 JP 2011509829 A JP2011509829 A JP 2011509829A JP 2011509829 A JP2011509829 A JP 2011509829A JP 2011524340 A5 JP2011524340 A5 JP 2011524340A5
- Authority
- JP
- Japan
- Prior art keywords
- aryl
- heteroaryl
- alkyl
- heterocyclyl
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 125000003118 aryl group Chemical group 0.000 claims 31
- 150000001875 compounds Chemical class 0.000 claims 30
- 125000001072 heteroaryl group Chemical group 0.000 claims 30
- 125000000623 heterocyclic group Chemical group 0.000 claims 29
- 125000000753 cycloalkyl group Chemical group 0.000 claims 23
- 125000003275 alpha amino acid group Chemical group 0.000 claims 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 18
- 201000010099 disease Diseases 0.000 claims 16
- 238000000034 method Methods 0.000 claims 10
- 125000001188 haloalkyl group Chemical group 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 125000000539 amino acid group Chemical group 0.000 claims 8
- 102000011727 Caspases Human genes 0.000 claims 7
- 108010076667 Caspases Proteins 0.000 claims 7
- 229910052736 halogen Inorganic materials 0.000 claims 7
- 150000002367 halogens Chemical class 0.000 claims 7
- 230000001404 mediated effect Effects 0.000 claims 4
- MKFDYOISVJDNKS-UHFFFAOYSA-N 2-(2,3-dihydro-1h-inden-1-ylamino)acetic acid Chemical compound C1=CC=C2C(NCC(=O)O)CCC2=C1 MKFDYOISVJDNKS-UHFFFAOYSA-N 0.000 claims 3
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 claims 3
- 230000006907 apoptotic process Effects 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 206010055128 Autoimmune neutropenia Diseases 0.000 claims 2
- 208000011594 Autoinflammatory disease Diseases 0.000 claims 2
- 208000023328 Basedow disease Diseases 0.000 claims 2
- 201000006474 Brain Ischemia Diseases 0.000 claims 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims 2
- 208000035473 Communicable disease Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 206010058314 Dysplasia Diseases 0.000 claims 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 2
- 208000015023 Graves' disease Diseases 0.000 claims 2
- 208000031886 HIV Infections Diseases 0.000 claims 2
- 208000037357 HIV infectious disease Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 2
- 208000005176 Hepatitis C Diseases 0.000 claims 2
- 206010019773 Hepatitis G Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 102000000589 Interleukin-1 Human genes 0.000 claims 2
- 108010002352 Interleukin-1 Proteins 0.000 claims 2
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 2
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 206010033645 Pancreatitis Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 208000017442 Retinal disease Diseases 0.000 claims 2
- 206010039710 Scleroderma Diseases 0.000 claims 2
- 206010040047 Sepsis Diseases 0.000 claims 2
- 206010040070 Septic Shock Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 230000032683 aging Effects 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 210000001367 artery Anatomy 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 230000003143 atherosclerotic effect Effects 0.000 claims 2
- 201000005000 autoimmune gastritis Diseases 0.000 claims 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 206010008118 cerebral infarction Diseases 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 230000008878 coupling Effects 0.000 claims 2
- 238000010168 coupling process Methods 0.000 claims 2
- 238000005859 coupling reaction Methods 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 206010014599 encephalitis Diseases 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 208000024908 graft versus host disease Diseases 0.000 claims 2
- 208000019622 heart disease Diseases 0.000 claims 2
- 208000006454 hepatitis Diseases 0.000 claims 2
- 231100000283 hepatitis Toxicity 0.000 claims 2
- 208000002672 hepatitis B Diseases 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 208000021039 metastatic melanoma Diseases 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 208000031225 myocardial ischemia Diseases 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 230000000926 neurological effect Effects 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 206010034674 peritonitis Diseases 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 125000006239 protecting group Chemical group 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 230000036303 septic shock Effects 0.000 claims 2
- 208000020431 spinal cord injury Diseases 0.000 claims 2
- 208000002320 spinal muscular atrophy Diseases 0.000 claims 2
- 238000003786 synthesis reaction Methods 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 206010043554 thrombocytopenia Diseases 0.000 claims 2
- 230000009529 traumatic brain injury Effects 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000007822 coupling agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000149 penetrating effect Effects 0.000 claims 1
- 239000000816 peptidomimetic Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 0 *[C@@](C(N)=O)N* Chemical compound *[C@@](C(N)=O)N* 0.000 description 7
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12825308P | 2008-05-21 | 2008-05-21 | |
| US61/128,253 | 2008-05-21 | ||
| PCT/CA2009/000696 WO2009140765A1 (en) | 2008-05-21 | 2009-05-21 | Selective caspase inhibitors and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014265816A Division JP5995951B2 (ja) | 2008-05-21 | 2014-12-26 | 選択的カスパーゼ阻害剤およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011524340A JP2011524340A (ja) | 2011-09-01 |
| JP2011524340A5 true JP2011524340A5 (enExample) | 2012-06-21 |
Family
ID=41339699
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011509829A Ceased JP2011524340A (ja) | 2008-05-21 | 2009-05-21 | 選択的カスパーゼ阻害剤およびその使用 |
| JP2014265816A Expired - Fee Related JP5995951B2 (ja) | 2008-05-21 | 2014-12-26 | 選択的カスパーゼ阻害剤およびその使用 |
| JP2016162904A Pending JP2017039723A (ja) | 2008-05-21 | 2016-08-23 | 選択的カスパーゼ阻害剤およびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014265816A Expired - Fee Related JP5995951B2 (ja) | 2008-05-21 | 2014-12-26 | 選択的カスパーゼ阻害剤およびその使用 |
| JP2016162904A Pending JP2017039723A (ja) | 2008-05-21 | 2016-08-23 | 選択的カスパーゼ阻害剤およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US8791235B2 (enExample) |
| EP (1) | EP2288615B1 (enExample) |
| JP (3) | JP2011524340A (enExample) |
| CN (1) | CN102105485B (enExample) |
| AU (1) | AU2009250295B2 (enExample) |
| CA (1) | CA2724785C (enExample) |
| DK (1) | DK2288615T3 (enExample) |
| ES (1) | ES2640814T3 (enExample) |
| IL (1) | IL209407A0 (enExample) |
| SG (1) | SG191591A1 (enExample) |
| WO (1) | WO2009140765A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2288615B1 (en) * | 2008-05-21 | 2017-06-21 | Genesis Technologies Limited | Selective caspase inhibitors and uses thereof |
| US9045524B2 (en) | 2009-05-21 | 2015-06-02 | Novagenesis Foundation | Selective caspase inhibitors and uses thereof |
| DK2697246T3 (en) | 2011-04-15 | 2018-05-28 | Genesis Tech Limited | SELECTIVE CYSTEIN PROTEASE INHIBITORS AND USES THEREOF |
| US9956260B1 (en) | 2011-07-22 | 2018-05-01 | The J. David Gladstone Institutes | Treatment of HIV-1 infection and AIDS |
| WO2014060942A2 (en) * | 2012-10-20 | 2014-04-24 | Mahesh Kandula | Compositions and methods of for the treatment of multiple sclerosis and neurodegenerative diseases |
| CN103936838B (zh) * | 2014-04-10 | 2015-10-28 | 武汉启瑞科技发展有限公司 | 小分子多肽TAT-p53DM及其在制备治疗或预防缺血性卒中药物中的应用 |
| WO2017143237A1 (en) * | 2016-02-17 | 2017-08-24 | Acetylon Pharmaceuticals, Inc. | Increasing expression of interferon regulated genes with combinatons of histone deacetylase inhibitors and immunomodulatory drugs |
| CN108484668A (zh) * | 2018-04-25 | 2018-09-04 | 中山大学 | 具有磺酰基官能团的有机膦化合物及其制备方法和应用 |
| CN108467409A (zh) * | 2018-04-25 | 2018-08-31 | 中山大学 | 具有磺酰基官能团的五价膦化合物及其制备方法和应用 |
| WO2019206166A1 (zh) * | 2018-04-25 | 2019-10-31 | 中山大学 | 具有磺酰基官能团的有机膦化合物及其制备方法和应用 |
| CN116987116B (zh) * | 2023-09-26 | 2023-12-01 | 常州合全药业有限公司 | 一种甲硫甲基磷酸二乙酯的连续合成方法 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3341331A (en) * | 1964-03-23 | 1967-09-12 | Fuji Photo Film Co Ltd | Photographic silver halide materials utilizing succinmonoamido benzoyl acetanilide color couplers |
| JPS4818256B1 (enExample) * | 1968-05-20 | 1973-06-05 | ||
| IT974398B (it) * | 1971-12-28 | 1974-06-20 | Fuji Photo Film Co Ltd | Metodo per produrre immagini fotografiche e materiale foto sensibile per eseguirlo |
| CA2012306A1 (en) | 1989-03-28 | 1990-09-28 | Werner Neidhart | Amino acid derivatives |
| IL112759A0 (en) * | 1994-02-25 | 1995-05-26 | Khepri Pharmaceuticals Inc | Novel cysteine protease inhibitors |
| CZ298197A3 (cs) * | 1995-03-24 | 1998-03-18 | Arris Pharmaceutical Corporation | Reverzibilní inhibitory proteas |
| CA2215211A1 (en) * | 1995-03-31 | 1996-10-03 | Takeda Chemical Industries, Ltd. | Cysteine protease inhibitor |
| ES2242225T3 (es) | 1996-05-14 | 2005-11-01 | Agouron Pharmaceuticals, Inc. | Inhibidores de proteasas 3c antipicornavirales y procedimientos correspondientes de utilizacion y de preparacion. |
| AU728006B2 (en) | 1997-03-24 | 2001-01-04 | Merck & Co., Inc. | Thrombin inhibitors |
| US5962487A (en) | 1997-12-16 | 1999-10-05 | Agouron Pharmaceuticals, Inc. | Antipicornaviral compounds and methods for their use and preparation |
| IL138048A0 (en) | 1998-03-26 | 2001-10-31 | Univ Dundee | Use of inhibitors of mammalian asparaginyl endopeptidase for therapy of autoimmune disease |
| TR200003159T2 (tr) | 1998-04-30 | 2001-09-21 | Agouron Pharmaceuticals,Inc. | Antipicornaviral bileşikler, hazırlanışları ve kullanımları |
| AR026748A1 (es) * | 1999-12-08 | 2003-02-26 | Vertex Pharma | Un compuesto inhibidor de caspasas, una composicion farmaceutica que lo comprende, un metodo para la sintesis del mismo y un compuesto intermediario paradicha sintesis |
| NZ516918A (en) * | 2000-05-23 | 2004-06-25 | Vertex Pharma | Caspase inhibitors and uses thereof |
| ATE301642T1 (de) | 2000-06-06 | 2005-08-15 | Warner Lambert Co | Bicyclische cyclohexylamine und ihre verwendung als nmda-rezeptor antagonisten |
| DE60131160T2 (de) * | 2000-06-07 | 2008-08-07 | Vertex Pharmaceuticals Inc., Cambridge | Caspase-inhibitoren und ihre verwendungen |
| JP2004509120A (ja) | 2000-09-13 | 2004-03-25 | バーテックス ファーマシューティカルズ インコーポレイテッド | カスパーゼ阻害剤およびそれらの用途 |
| JP2002145848A (ja) | 2000-11-10 | 2002-05-22 | Kyorin Pharmaceut Co Ltd | アルケニルアミノ酸誘導体及びその製造法 |
| EP1341767B1 (en) | 2000-11-21 | 2007-04-11 | Vertex Pharmaceuticals Incorporated | Imidazole and benzimidazole caspase inhibitors and uses thereof |
| AU2002328946A1 (en) | 2001-08-13 | 2003-03-03 | Probiodrug Ag | Irreversible cysteine protease inhibitors of legumain |
| JP2005509028A (ja) | 2001-10-09 | 2005-04-07 | バーテックス ファーマシューティカルズ インコーポレイテッド | アスパラギン酸およびグルタミン酸誘導体ならびにそのジアゾケトン中間体を合成するための方法 |
| US7118877B2 (en) | 2002-07-08 | 2006-10-10 | Wyeth | Caspase 9 activation and uses therefor |
| CN1240712C (zh) * | 2003-05-09 | 2006-02-08 | 深圳市康哲药业有限公司 | 制备酪－丝－亮三肽的方法 |
| KR100594544B1 (ko) | 2003-08-27 | 2006-06-30 | 주식회사 엘지생명과학 | 이소옥사졸린 구조를 갖는 캐스파제 저해제 |
| US7256198B2 (en) * | 2004-02-18 | 2007-08-14 | Wyeth | Pyrimidoindolones and methods for using same |
| US20080220416A1 (en) | 2004-05-20 | 2008-09-11 | The Board Of Trustees Of The University Of Illinoi | Compositions for Inhibiting Cell Growth and Inducing Apoptosis in Cancer Cells and Methods of Use Thereof |
| TW200626611A (en) | 2004-09-20 | 2006-08-01 | Lonza Ag | Peptide cyclisation |
| EP1817328A2 (en) | 2004-11-24 | 2007-08-15 | Theraptosis S.A. | New peptides useful as dual caspase-2/-6 inhibitors and their biological applications |
| GB0502277D0 (en) | 2005-02-04 | 2005-03-09 | Amersham Plc | Novel imaging agents |
| US7589066B2 (en) | 2005-03-11 | 2009-09-15 | The University Of North Carolina At Chapel Hill | Potent and specific immunoproteasome inhibitors |
| AU2006201635A1 (en) * | 2005-10-20 | 2007-05-10 | Ludwig Institute For Cancer Research | Novel inhibitors and methods for their preparation |
| JP2009542689A (ja) * | 2006-07-07 | 2009-12-03 | ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ | 選択的カスパーゼ阻害剤 |
| CN101161672A (zh) * | 2007-11-28 | 2008-04-16 | 吉林大学 | 精氨酸-甘氨酸-天冬氨酸细胞粘附三肽的制备方法 |
| EP2288615B1 (en) | 2008-05-21 | 2017-06-21 | Genesis Technologies Limited | Selective caspase inhibitors and uses thereof |
| DE202009007220U1 (de) | 2009-05-19 | 2010-10-28 | Puma Ag Rudolf Dassler Sport | Schuh, insbesondere Sportschuh |
| US9045524B2 (en) | 2009-05-21 | 2015-06-02 | Novagenesis Foundation | Selective caspase inhibitors and uses thereof |
| DK2697246T3 (en) | 2011-04-15 | 2018-05-28 | Genesis Tech Limited | SELECTIVE CYSTEIN PROTEASE INHIBITORS AND USES THEREOF |
-
2009
- 2009-05-21 EP EP09749369.6A patent/EP2288615B1/en not_active Not-in-force
- 2009-05-21 ES ES09749369.6T patent/ES2640814T3/es active Active
- 2009-05-21 WO PCT/CA2009/000696 patent/WO2009140765A1/en not_active Ceased
- 2009-05-21 AU AU2009250295A patent/AU2009250295B2/en not_active Ceased
- 2009-05-21 CA CA2724785A patent/CA2724785C/en active Active
- 2009-05-21 JP JP2011509829A patent/JP2011524340A/ja not_active Ceased
- 2009-05-21 SG SG2013038997A patent/SG191591A1/en unknown
- 2009-05-21 CN CN200980128709.7A patent/CN102105485B/zh not_active Expired - Fee Related
- 2009-05-21 US US12/993,565 patent/US8791235B2/en active Active
- 2009-05-21 DK DK09749369.6T patent/DK2288615T3/en active
-
2010
- 2010-11-18 IL IL209407A patent/IL209407A0/en active IP Right Grant
-
2014
- 2014-06-17 US US14/307,025 patent/US9562069B2/en active Active
- 2014-12-26 JP JP2014265816A patent/JP5995951B2/ja not_active Expired - Fee Related
-
2016
- 2016-08-23 JP JP2016162904A patent/JP2017039723A/ja active Pending
-
2017
- 2017-01-06 US US15/400,323 patent/US10167313B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2020111238A1 (ja) | ペプチド化合物、またはアミド化合物の脱保護法および固相反応における脱樹脂方法、並びにペプチド化合物の製造方法 | |
| CA2967385C (en) | Methods of manufacturing treprostinil and treprostinil derivative prodrugs | |
| EA200500660A1 (ru) | Трициклические соединения - ингибиторы интегразы вич, способ их получения (варианты), фармацевтическая композиция на их основе, способ ее получения и способы их использования в лечении болезней | |
| JP2003535865A5 (enExample) | ||
| GB0804701D0 (en) | Compounds | |
| RU2005102094A (ru) | Ингибиторы каспазы и их применение | |
| CA2536887A1 (en) | Pyrrolopyrimidinone derivatives | |
| CA2286722C (en) | Peptidyl-2-amino-1-hydroxyalkanesulfonic acid cysteine protease inhibitors | |
| CY1113340T1 (el) | Ενωσεις | |
| TW442452B (en) | Serine protease inhibitors having an alkynylamino side chain | |
| AU2014310619B2 (en) | Peptide-oligourea chimeric compounds and methods of their use | |
| JP2013514980A5 (enExample) | ||
| DE102006052755A1 (de) | Michaelsysteme als Transglutaminaseinhibitoren | |
| JP2014511877A5 (enExample) | ||
| JP2011524340A (ja) | 選択的カスパーゼ阻害剤およびその使用 | |
| JP2011518176A5 (enExample) | ||
| RU2008107576A (ru) | Пролекарства ингибитора каспазы | |
| JP2007525503A5 (enExample) | ||
| Petrov et al. | Synthesis and evaluation of 3-aminopropionyl substituted fentanyl analogues for opioid activity | |
| CA2576647A1 (en) | Vla-4 antagonists | |
| JP2015504426A5 (enExample) | ||
| RU2014116550A (ru) | Гликозилированный полипептид и содержащая его фармацевтическая композиция | |
| CN103827100B (zh) | 用于降低血清尿酸的[1,2,4]噻二嗪1,1-二氧化物化合物 | |
| RU2002121482A (ru) | Пирролопиридазиновые производные | |
| JP2005510559A5 (enExample) |